FDA Panels Back Excedrin For Migraine

16 July 1997

Three US Food and Drug Administration advisory committees haverecommended by a unanimous vote that Bristol-Myers Squibb's Excedrin Extra Strength (acetaminophen) is an effective over-the-counter analgesic for the relief of migraine.

If the FDA follows the recommendation, the 20-year-old Excedrin product will become the first and only approved OTC medication for migraine with a sound clinical database.

B-MS conducted three clinical trials including a total of 1,250 migraine sufferers in its dossier for the new indication. The results of these studies suggest that Excedrin, when given for the acute treatment of a migraine attack, reduced pain to "mild" or "none" in 59% of patients at two hours, and 79% at six hours.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight